CPDA-1 - anticoagulant citrate phosphate dextrose adenine solution Fenwal. Inc.

Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) BLOOD-PACK™ Unit

Instructions for Blood Collection Using Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) BLOOD-PACK™ Units

4R3622, 4R3626

FRESENIUS KABI

Fenwal Blood-Pack Units

Rx only

Using Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) and Fenwal HighFlo Needle

Instructions for Use

Collection Procedure:

Use aseptic technique

Note: Nominal tubing dimensions of product are 0.118" inner diameter x 0.025" wall thickness.

Note: If the Y-Sampling Site is not used, donor samples may be collected using an alternate method following standard procedures.

Precautions:

- Do not use unless the solution is clear.
- Before beginning procedure, obtain one access device for each Blood-Pack unit with Y-Sampling Site to be processed.
- 1. Identify Blood-Pack unit using appropriate donor identification system.
- 2. Adjust donor scale to desired collection weight and position primary container on the donor scale as far as possible below donor arm.
- 3. Clamp donor tubing between Fenwal HighFlo1 needle and primary container. This step may be performed prior to step 1 or 2.
- 4. Following blood center procedures, apply pressure to donor's arm and disinfect site of venipuncture.
- 5. Remove needle cover per instructions below:
- a) Holding the hub and cover near the tamper-evident seal, twist cover and hub in opposite directions to break seal.
- b) Remove needle cover, being careful not to drag the cover across the needle point.
- 6. Following blood center procedures, perform venipuncture, appropriately secure donor needle and/or tubing and release clamp on donor tubing.

- 7. When good blood flow is established, stabilize the front of the needle guard to arm with tape. (see Figure 1)
- 8. Mix blood and anticoagulant in primary container at several intervals during collection and immediately after collection.
- 9. Collect the appropriate volume based on Blood-Pack unit used.

Note: The volume of anticoagulant is sufficient for the blood collection indicated on Blood-Pack unit \pm 10%.

10. Release the pressure on the donor's arm as appropriate.

Precaution: Do not proceed with the remaining steps until the entire whole blood unit is collected.

11. To avoid possible contamination of the whole blood unit, before filling whole blood sample tubes, hermetically seal the donor tubing near the Y-Sampling Site on the side leading to the primary container using a metal clip or appropriate alternate method.

Precaution: Complete steps 12 - 20 within approximately 4 minutes after sealing the donor tubing to avoid possible clot formation in the tubing.

12. To collect samples, insert the access device by pushing firmly into the Y-Sampling Site until the membrane seal is penetrated (see Figure 2).

Note: If the access device is assembled such that the outer barrel is screwed onto the Luer, make sure to rotate clockwise upon insertion to avoid barrel detaching from Luer.

- 13. Open the cap on the access device (if applicable).
- 14. Directly align the vacuum sample tube with the internal needle in the access device. Insert vacuum sample tube into device until the stopper is punctured.
- 15. Allow vacuum sample tube to fill with blood then remove from the access device.
- 16. Repeat steps 14 and 15 until the desired number of vacuum sample tubes have been filled.

Notes:

- If the access device needs to be replaced, clamp the tubing between the needle and the Y-Sampling Site. Then, grasp base of Sampling Site with one hand and pull the access device out with the other hand. Firmly insert the new access device. Remove clamp and continue sampling.
- If the access device is assembled such that the outer barrel is screwed onto the Luer, make sure to rotate clockwise upon removal to avoid barrel detaching from Luer.
- The access device can only be replaced one time.

Precaution: When replacing the access device, be careful to avoid contact with any blood droplets on the Luer or Sampling Site. Discard used access device appropriately.

- 17. Release remaining pressure on donor's arm.
- 18. If desired, apply clamp to donor tubing between needle and Y-Sampling Site.
- 19. Withdrawal of Needle (see Figure 3)

Precaution: The needle guard must be held stationary while the needle is withdrawn into it.

- a) Place folded sterile gauze over puncture site and hold in place with finger tip without exerting pressure.
- b) Hold sides of the needle guard near the front, between the index finger and thumb. Pull the hub back smoothly until the needle is completely enclosed and securely locked into the needle guard.
- c) Confirm the needle is completely enclosed and securely locked into the needle guard.
- 20. Strip blood from donor tubing into primary container, mix and allow the tubing to

refill; repeat once.

21. Seal at X marks on donor tubing to provide numbered aliquots of anticoagulated blood for typing or crossmatching.

Note: Step 22 may be performed prior to step 20 or 21 if desired.

22. Remove and discard the Y-Sampling Site and the donor needle in the needle guard into an appropriate biohazardous waste container following established procedures.

23. Component Preparation:

- If a platelet concentrate is to be prepared, it should be separated from the red blood cells within 8 hours after blood collection.
- Fresh frozen plasma should be separated from the red blood cells and placed in the freezer at -18°C or colder within 8 hours after blood collection.
- 24. At the appropriate time, prepare the Blood-Pack unit for centrifugation by thoroughly mixing the primary container end over end, then load the unit in a centrifuge cup per the instructions on page 3.
- 25. Following centrifugation, remove containers from the centrifugation cup taking care not to disturb the red blood cell / plasma interface.
- 26. Place primary container in plasma extractor and express plasma into the appropriate empty Transfer Pack container by releasing pressure plate and opening closure in tubing of primary container.
- 27. When desired amount of plasma has been removed, clamp tubing between Y and plasma container.
- 28. Hermetically seal and separate transfer tubing between the Y-connector and primary container. Be careful to avoid fluid splatter.
- 29. For further processing with multiple Blood-Pack units, use standard component processing and storage techniques.
- 30. Store suspended CPDA-1 Whole Blood/Red Blood Cells between 1 and 6°C.
- 31. Infuse CPDA-1 Whole Blood/Red Blood Cells within 35 days of collection.



Figure 1





Figure 2



Figure 3



Representative Product Drawing

Store at Controlled Room Temperature. Protect from freezing. Avoid excessive heat. Definition of "Controlled Room Temperature":

"A temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25° C (68° to 77° F); that results in a mean kinetic temperature calculated to be not more than 25° C; and that allows for excursions

between 15°C and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses. Provided the mean kinetic temperature remains in the allowed range, transient spikes up to 40°C are permitted as long as they do not exceed 24 hours ... The mean kinetic temperature is a calculated value that may be used as an isothermal storage temperature that simulates the non isothermal effects of storage temperature variations."

Reference: United States Pharmacopeia, General Notices. United States Pharmacopeial Convention, Inc. 12601 Twinbrook Parkway, Rockville, MD.

Symbols with Definitions:

↑ Caution, consult instructions for use

Sterilized by steam. Sterile fluid path.

Non-pyrogenic fluid path

Do not reuse


Do not vent

This way up

LOT Lot

REF Code


Centrifuge Cup Loading Instructions BPU without Filter




Place the Blood-Pack unit on a work surface. Separate the containers keeping the satellite containers together with Adsol container on top and label side down. Place segments on the middle of the satellite containers.



2 Fold satellite containers over segments. Coil tubing on top of tolded containers. Ensure Y-connector is at side of folded containers.



3 Place folded satellite containers on primary container as shown. Satellite containers are horizontally placed with tabs/tubing facing out. Y-connector is oriented at the top and the extra tubing is placed to the outside of the bundle.



4 Sorvall® Blood Bag Insert#11365 is recommended for use with oval centritude cups or when there is excess space inside the cup. If excess space inside the cup is not filled, the blood bag can over expand and break.



5 If used, inserts are placed on back of bundle. Do not place inserts between satellite containers and primary container or at the front of the primary container.



6 Hold the bundle and insert into the centrifuge cup.



7 Press the satellite containers (and inserts if used) down into the liner before pressing down the primary container.

for complete instructions, precautions, and warnings.

This guide illustrates one method of cup loading and applies to

all non-filter BPU configurations. The specific stacking order and methods may vary depending on the centrifuge equipment and your facility's Standard Operating Procedures. See Directions for Use



8 After the satellite containers have been pressed down, press the primary container down into the liner.



9 When finished, the cannula is in the upright position, the Y-connector is at the top away from the primary container, segments are secured inside the satellite containers, and the unit is down inside the cup.

Perform centrifugation according to center procedures.

Manufacturer Fresenius Kabi AG 61346 Bad Homburg / Germany www.fresenius-kabi.com

1-800-933-6925

47-23-13-520 REV: A

Sorvall is a trademark of Thermo Fisher Scientific LLC.

© 2019 Fresenius Kabi AG. All rights reserved

¹ Van der Meer, P.F., & de Korte, D. "Increase of blood donation speed by optimizing the needle-to-tubing connection: an application of donation software." Vox Sanguinis 2009, 97: 21-25

PACKAGE/LABEL DISPLAY PANEL

Code 4R3626

24 Units

Fenwal Blood-Pack Units Double

Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1)

For Collection and Processing of 500 mL Blood

Y-Sampling Site 16 ga. Ultra Thin Wall Fenwal HighFlo Needle

Rx only

Each unit consists of a primary container with 70 mL of CPDA-1 solution containing 2.23 g Dextrose (monohydrate) USP, 1.84 g Sodium Citrate (dihydrate) USP, 209 mg Citric Acid (anhydrous) USP, 155 mg Monobasic Sodium Phosphate (monohydrate) USP and 19.3 mg Adenine USP, pH may have been adjusted with sodium hydroxide; one empty 400 mL Transfer Pack container.

Sterile, non-pyrogenic fluid path. See instructions for use.

Single use only.

Store at Controlled Room Temperature (refer to direction insert). Protect from freezing. Avoid excessive heat.

- Open pouch by tearing across at notch.
- Direct handling of product surfaces prior to extended storage in the **foil** pouch, may result in mold growth.
- Unused units in open **foil** pouch may be kept up to 60 days by folding and **securing** open end of **foil** pouch to prevent possible loss of moisture, provided:
 - 1. Units are not removed from **foil** pouch, or
 - 2. Unused units removed from **foil** pouch are returned to the foil pouch within 12 hours. Units may be removed from the pouch and returned only once.
- Units removed from the **foil** pouch (that are not returned to the pouch within 12 hours) must be used within 4 days (96 hours). Units out of the **foil** pouch for longer than 96 hours must be discarded.

Manufacturer
Fresenius Kabi AG.
61346 Bad Homburg / Germany
www.fresenius-kabi.com

Made in US

47-28-13-511 REV:A

Fenwal Blood-Pack Units

Double

Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1)

For Collection and Processing of 500 mL Blood Y-Sampling Site, 16 ga. Ultra Thin Wall Fenwal HighFlo Needle

Rx only

Each unit consists of a primary container with 70 mL of CPDA-1 solution containing 2.23 g Dextrose (monohydrate) USP, 1.84 g Sodium Citrate (dihydrate) USP, 209 mg Citric Acid (anhydrous) USP, 155 mg Monobasic Sodium Phosphate (monohydrate) USP and 19.3 mg Adenine USP, pH may have been adjusted with sodium hydroxide; one empty 400 mL Transfer Pack container.

Sterile, non-pyrogenic fluid path. See instructions for use.

Single use only.

Store at Controlled Room Temperature (refer to direction insert). Protect from freezing. Avoid excessive heat.

- Open pouch by tearing across at notch.
- Direct handling of product surfaces prior to extended storage in the foil pouch, may result in mold growth.
- Unused units in open foil pouch may be kept up to 60 days by folding and securing open end of foil pouch to prevent possible loss of moisture, provided:
 - I) Units are not removed from foil pouch, or
 - II) Unused units removed from foil pouch are returned to the foil pouch within 12 hours. Units may be removed from the pouch and returned only once.
- Units removed from the foil pouch (that are not returned to the pouch within 12 hours) must be used within 4 days (96 hours). Units out of the foil pouch for longer than 96 hours must be discarded.



+M5264R36262/

Manufacturer
Fresenius Kabi AG
61346 Bad Homburg / Germany
www.fresenius-kabi.com

Made in US

47-28-13-511 REV: A



CPDA-1

anticoagulant citrate phosphate dextrose adenine solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0942-9393
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety				
Ingredient Name	Basis of Strength	Strength		
Dextrose Monohydrate (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	Dextrose Monohydrate	2.23 g in 70 mL		
Trisodium Citrate Dihydrate (UNII: B22547B95K) (Anhydrous Citric Acid - UNII:XF417D3PSL)	Anhydrous Citric Acid	1.84 g in 70 mL		
Anhydrous Citric Acid (UNII: XF417D3PSL) (Anhydrous Citric Acid - UNII:XF417D3PSL)	Anhydrous Citric Acid	209 mg in 70 mL		
Sodium Phosphate, Monobasic, Monohydrate (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR)	Sodium Phosphate, Monobasic, Monohydrate	155 mg in 70 mL		
Adenine (UNII: JAC85A2161) (Adenine - UNII:JAC85A2161)	Adenine	19.3 mg in 70 mL		

Inactive Ingredients			
Ingredient Name	Strength		
Sodium Hydroxide (UNII: 55X04QC32I)			

Packaging					
	#	Item Code	Package Description	Marketing Start Date	Marketing End Date
		NDC:0942-9393- 02	70 mL in 1 BAG; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	BN770420	03/01/2007	

Labeler - Fenwal, Inc. (794519020)

Establishment				
Name	Address	ID/FEI	Business Operations	
Fenwal International, Inc.		091164590	MANUFACTURE(0942-9393), ANALYSIS(0942-9393), LABEL(0942-9393), PACK(0942-9393), STERILIZE(0942-9393)	

Revised: 12/2021 Fenwal, Inc.